Alliance Clinical Network and Atlas Clinical Research Complete Merger to Create Expanded National Clinical Research Platform
Alliance Clinical Network and Atlas Clinical Research have announced the successful completion of a strategic merger, creating an expanded clinical research organization with nearly five decades of combined experience in supporting clinical trials across the United States. The transaction brings together two established site networks with complementary strengths, shared values, and a common vision focused on improving clinical trial quality, patient access, operational efficiency, and research execution.
The merger represents a significant development within the Alliance clinical research industry as pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) increasingly seek research partners capable of delivering high-quality data, rapid patient enrollment, geographic diversity, and consistent operational performance. By combining their resources, expertise, and site infrastructure, Alliance Clinical Network and Atlas Clinical Research aim to create a stronger platform capable of addressing the evolving demands of modern drug development.
The newly combined organization will operate across multiple major research markets, with Alliance clinical trial sites located throughout Arizona, California, Florida, Nevada, New York, Pennsylvania, and Texas. Leadership from both companies believes the merger will strengthen their ability to support sponsors conducting increasingly complex clinical studies while expanding access to research opportunities for diverse patient populations.
Bringing Together Decades of Clinical Research Experience
The merger combines nearly 50 years of collective experience in clinical trial management and patient recruitment. Throughout their histories, both organizations have established reputations for delivering high-quality research services while maintaining a strong focus on patient care and regulatory compliance.
Clinical research has become increasingly sophisticated in recent years, with new therapies targeting highly specific patient populations and requiring more specialized study designs. As a result, sponsors are looking for site networks that can provide broad therapeutic expertise while maintaining consistent standards across multiple locations.
The leadership teams of Alliance and Atlas noted that the organizations share similar values centered on quality, collaboration, integrity, diversity, and operational excellence. These common principles helped create a strong strategic fit between the two companies and laid the foundation for the integration.
By combining their capabilities, the merged organization expects to offer sponsors a more streamlined and scalable clinical trial experience while preserving the personalized approach that has helped both companies build long-standing relationships with pharmaceutical and biotechnology partners.
Expanding Therapeutic Expertise
One of the most significant benefits of the merger is the expansion of therapeutic capabilities across a broad range of medical specialties.
The combined organization will support clinical research programs in numerous therapeutic areas, including central nervous system (CNS) disorders, dermatology, gastroenterology, internal medicine, metabolic diseases, pain management, vaccines, and women’s health.
These expanded capabilities position the company to participate in a wider variety of clinical development programs, ranging from early-stage investigational therapies to large-scale late-stage clinical trials.
The growing complexity of clinical research often requires specialized expertise in disease management, patient recruitment, protocol execution, and data collection. By integrating the therapeutic strengths of both organizations, the combined company expects to provide sponsors with deeper clinical knowledge and enhanced operational support across multiple indications.
This broader therapeutic reach may also allow the organization to pursue new research opportunities in areas experiencing significant innovation, including metabolic disorders, neurological diseases, immunology, and preventive medicine.
Strengthening Geographic Coverage Across the United States
Another major advantage of the merger is the substantial expansion of the company’s geographic footprint.
Following the transaction, the combined network will operate sites across seven states, creating a presence in several important clinical research markets throughout the country.
The expanded footprint is expected to improve patient recruitment capabilities by providing access to larger and more diverse populations. Recruiting appropriate patients remains one of the most significant challenges in clinical development, and delays in enrollment can significantly impact study timelines and development costs.
With locations spanning the Southwest, West Coast, Northeast, Southeast, and Southern United States, the merged company will be positioned to reach a broad range of demographic groups and disease-specific patient populations.
This expanded geographic coverage may be particularly valuable for sponsors seeking greater diversity in clinical trial participation. Regulatory agencies and healthcare stakeholders have increasingly emphasized the importance of enrolling patient populations that more accurately reflect real-world demographics.
By leveraging multiple research clusters across the country, the organization hopes to improve patient access to clinical trials while helping sponsors achieve more representative enrollment goals.
Improving Patient Access and Diversity in Clinical Research
Increasing patient access to clinical research opportunities has become a central objective across the healthcare industry.
Many patients remain unaware of available clinical trials or face barriers related to geography, transportation, healthcare access, and awareness. The expanded network created through the merger is expected to help address some of these challenges by providing more localized opportunities for participation.
The company plans to utilize its broader infrastructure and disease-specific expertise to reach patient populations that have historically been underrepresented in clinical research.
Improved diversity in clinical trials not only supports equity in healthcare but also enhances the quality and applicability of research findings. By ensuring that studies include participants from varied racial, ethnic, geographic, and socioeconomic backgrounds, sponsors can generate data that more accurately reflects how treatments perform in real-world populations.
Leadership from both organizations indicated that expanding access to diverse patient communities remains an important component of their long-term strategy.
Enhancing Operational Excellence
Beyond geographic expansion and therapeutic growth, the merger is expected to create operational efficiencies that improve study execution and overall trial performance.
The combined organization plans to align and optimize proprietary internal centers of excellence, bringing together operational best practices developed by both companies over many years.
Clinical trial sponsors increasingly prioritize consistency, predictability, and efficiency when selecting research partners. By standardizing processes and integrating successful operational models across the network, the company aims to deliver more reliable study performance while maintaining high standards of patient care.
The integration is expected to support faster startup timelines, improved enrollment strategies, enhanced data quality, and more effective site management practices.
At the same time, leadership emphasized that operational improvements will not come at the expense of patient-focused care. Maintaining high-quality interactions with trial participants and ensuring compliance with clinical research standards remain central priorities for the organization.
Leadership Perspective on the Merger
Anthony Milonas, Chief Executive Officer of Alliance Clinical Network, described the merger as an opportunity to create greater value for the clinical research industry and its stakeholders.
According to Milonas, the combined organization is well positioned to deliver predictable, transparent, and performance-driven results across a significantly expanded site network. He emphasized that bringing together the strengths of both organizations creates a platform capable of supporting sponsors more effectively while advancing the quality and efficiency of clinical trial execution.
Milonas also highlighted the importance of consistency and operational excellence as key differentiators in an increasingly competitive research environment.
As clinical studies become more complex and development timelines grow more demanding, sponsors are seeking research partners capable of delivering reliable performance across multiple therapeutic areas and geographic markets.
Creating a National Research Platform
Mark Scullion, Chief Executive Officer of Atlas Clinical Research, emphasized the strategic significance of the merger in expanding the company’s national reach.
He noted that the transaction creates a broad clinical research platform spanning several important healthcare markets across the United States. This expanded presence is expected to enhance the organization’s ability to support pharmaceutical and biotechnology companies as they navigate increasingly complex drug development programs.
Scullion also stressed that while the combined company will operate at a larger scale, it intends to preserve the culture, responsiveness, and quality standards that have contributed to the success of both organizations.
Maintaining strong relationships with sponsors, investigators, patients, and research staff will remain a priority as integration efforts move forward.
Support from Experienced Healthcare Investors
The merged company will continue to receive backing from Amulet Capital Partners and BPOC, two healthcare-focused private equity firms with extensive experience investing in and scaling healthcare services organizations.
The continued support of these investors is expected to provide financial resources and strategic guidance as the organization pursues growth opportunities and expands its capabilities.
Healthcare-focused private equity firms have played an increasingly important role in consolidating and modernizing clinical research infrastructure in recent years. Their involvement often supports investments in technology, operational improvements, geographic expansion, and talent development.
The leadership team believes that ongoing support from Amulet Capital Partners and BPOC will help accelerate the company’s growth strategy while maintaining a focus on quality and patient outcomes.
Following the completion of the merger, the combined organization will operate under the leadership of Anthony Milonas as Chief Executive Officer and will be headquartered in Southlake, Texas.
The new company enters its next phase with a substantially larger research footprint, expanded therapeutic expertise, enhanced patient recruitment capabilities, and a stronger operational foundation.
As demand for efficient, high-quality clinical research services continues to grow, the merged organization aims to position itself as a leading national partner for pharmaceutical companies, biotechnology innovators, and contract research organizations. By combining decades of experience with expanded geographic reach and therapeutic specialization, Alliance Clinical Network and Atlas Clinical Research intend to play a larger role in advancing clinical development programs and helping bring new therapies to patients across the United States.
About Alliance Clinical Network
Alliance Clinical Network is a fully integrated, wholly owned and operated clinical research site network helping to advance human health by delivering exceptional clinical trial data gathered from a proprietary, ready-to-tap diverse participant population.
About Atlas Clinical Research
Atlas Clinical Research is a network of clinical research sites providing access to a diverse range of patient populations, enabling the delivery of high-quality medical care, and increasing patient access to innovative treatments and technologies.
About Amulet Capital Partners
Amulet Capital Partners is a middle-market private equity investment firm based in Greenwich, CT, and Walnut Creek, CA, United States focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in healthcare companies, focusing on those segments it believes have the most attractive long-term fundamentals. Amulet currently manages approximately $2.5 billion of Regulatory Assets Under Management and is investing out of its third fund, which was oversubscribed and closed in July 2024 with approximately $1.2 billion in capital commitments.
About BPOC
Founded in 1996, BPOC is a Chicago-based private equity firm and one of the nation’s longest-tenured, pure play investors in the healthcare industry having raised seven funds with total capital commitments of approximately $2.5 billion. BPOC has invested in numerous provider, manufacturing, outsourcing, distribution and information technology companies through growth equity, management buyouts and leveraged recapitalizations.
